文献速递骨肌MR

对比增强与高级MRI序列能否提高不确定脂肪性肿瘤的诊断准确性?

Do contrast-enhanced and advanced MRI sequences improve diagnostic accuracy for indeterminate lipomatous tumors?
PubMed 文献 · Radiol Med · 2021-10-25

本研究回顾性纳入32例经组织学证实的外周脂肪性肿瘤患者,由两位骨肌放射科医生分三阶段阅片:仅非增强序列、加静态增强序列、再加DCE/DWI/CSI。结果显示增加对比增强、DWI或CSI并未提高诊断准确性(各阶段准确率53%、50%、53%),但厚分隔、≥1cm结节、DWI和CSI指标有助于鉴别良性、中间型与恶性肿瘤。

要点

  • 在常规非增强MRI基础上加做增强、DWI或CSI未提高脂肪性肿瘤诊断准确性。
  • 厚分隔(p=0.025)和≥1cm结节(p<0.001)有助于鉴别良性 from ALT/DDL。
  • DWI(p=0.01)和CSI(p=0.009)定量指标对鉴别诊断有潜在价值。

核心结论

  • 在传统非增强MRI方案中加入对比增强序列(静态、DCE)、DWI和CSI并未提高区分良性、中间型及恶性脂肪性肿瘤的诊断准确性。
  • 但DCE、DWI和CSI可识别出可能有助于鉴别这些病变的影像特征。

研究设计与样本

  • 回顾性研究,纳入32例连续患者,均为组织学证实的外周脂肪性肿瘤。
  • 两位骨肌放射科医生分三阶段阅片:第一阶段仅非增强T1WI和流体敏感序列;第二阶段加静态增强前后3D容积T1WI;第三阶段加DCE、DWI和CSI。
  • 每阶段阅片后记录诊断(良性、中间型/非典型脂肪瘤性肿瘤ALT、恶性/去分化脂肪肉瘤DDL),并记录分类影像特征和定量指标(ADC值、CSI信号丢失)。

关键影像表现/征象

  • 厚分隔(p=0.025)和结节≥1 cm(p<0.001)等非增强特征有助于鉴别良性肿瘤与ALT和DDL。
  • DWI指标(p=0.01)和CSI指标(p=0.009)也有助于鉴别。

诊断标准与关键数值

  • 诊断准确性:第一阶段53%(17/32),第二阶段50%(16/30),第三阶段53%(17/32),两读者均未因增加序列而提高。
  • 厚分隔p=0.025、结节≥1 cm p<0.001、DWI p=0.01、CSI p=0.009,用于鉴别良性 vs ALT/DDL。

临床应用与阅片要点

  • 日常阅片时应关注非增强MRI上的厚分隔和≥1 cm结节,这些特征对鉴别良性、中间型及恶性脂肪性肿瘤有提示作用。
  • 尽管DCE、DWI和CSI未整体提高诊断准确性,但可识别潜在有用特征,可在疑难病例中酌情参考。

局限性

  • 回顾性研究,样本量较小(32例),仅纳入组织学证实病例,可能存在选择偏倚。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Benign, intermediate-grade and malignant tumors sometimes have overlapping imaging and clinical characteristics. The purpose of this study was to evaluate the added value of contrast-enhanced sequences (dynamic contrast enhancement (DCE)), diffusion-weighted imaging (DWI), and chemical shift imaging (CSI) to noncontrast MRI sequences for the characterization of indeterminate lipomatous tumors.

MATERIALS AND METHODS: Thirty-two consecutive patients with histologically proven peripheral lipomatous tumors were retrospectively evaluated. Two musculoskeletal radiologists recorded the MRI features in three sessions: (1) with noncontrast T1-weighted and fluid-sensitive sequences; (2) with addition of static pre- and post-contrast 3D volumetric T1-weighted sequences; and (3) with addition of DCE, DWI, and CSI. After each session, readers recorded a diagnosis (benign, intermediate/atypical lipomatous tumor (ALT), or malignant/dedifferentiated liposarcoma (DDL)). Categorical imaging features (presence of septations, nodules, contrast enhancement) and quantitative metrics (apparent diffusion coefficient values, CSI signal loss) were recorded.

RESULTS: For 32 tumors, the diagnostic accuracy of both readers did not improve with the addition of contrast-enhanced sequences, DWI, or CSI (53% (17/32) session 1; 50% (16/30) session 2; 53% (17/32) session 3). Noncontrast features, including thick septations (p = 0.025) and nodules ≥ 1 cm (p < 0.001), were useful for differentiating benign tumors from ALTs and DDLs, as were DWI (p = 0.01) and CSI (p = 0.009) metrics.

CONCLUSION: The addition of contrast-enhanced sequences (static, DCE), DWI, and CSI to a conventional, noncontrast MRI protocol did not improve diagnostic accuracy for differentiating benign, intermediate-grade, and malignant lipomatous tumors. However, we identified potentially useful imaging features by DCE, DWI, and CSI that may help distinguish these entities.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Shannon BA, Ahlawat S, Morris CD, et al. Do contrast-enhanced and advanced MRI sequences improve diagnostic accuracy for indeterminate lipomatous tumors? Radiol Med. 2021. PMID: 34697728. doi:10.1007/s11547-021-01420-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。